AnaCardio is a clinical stage company developing novel drugs to treat heart failure. The company was founded based on ground-breaking research from Karolinska Institute (Sweden) showing improved contractility of the heart muscle through a unique and differentiated mechanism. 

The mode of action is novel and orthogonal to standard of care in patients with heart failure with reduced ejection fraction.

Sound Contact: Johan Kördel (Board Director)

Read an interview with CEO, Patrik Strömberg: Applying the best of both science and business to treat heart failure

Listen in to founder, Professor Lars Lund, discussing the findings from GOAL-HF1, the first study using our oral ghrelin agonist, AC01, in patients with HFrEF

Related news

AnaCardio´s Phase 1b/2a GOAL-HF1 study in patients with Heart Failure and Reduced Ejection Fraction (HFrEF) published in The Lancet

2026.06.252026.06.29 / Favourable safety profile in marked contrast to traditional inotropic therapeutics AC01 showed rapid and sustained improvements in cardiac output, structure and function STOCKHOLM, Sweden, [D …

Listen in to Professor Lars Lund, founder at AnaCardio, discussing the findings from GOAL-HF1, the first study using our oral ghrelin agonist, AC01, in patients with HFrEF

2026.06.082026.06.29 / https://soundbioventures.com/wp-content/uploads/2026/06/HFA-2026_-AC01-in-HFrEF-—-Safety-and-Efficacy-from-GOAL-HF1-_-AnaCardio-1.html …

AnaCardio Announces Phase 1b/2a GOAL-HF1 Results of AC01 Demonstrating Favorable Safety and Sustained Improvements in Cardiac Function on Top of Standard-of-Care Therapy in HFrEF

2026.05.112026.05.18 / STOCKHOLM, Sweden, May 11, 2026 – AnaCardio today announced detailed results from its Phase 1b/2a GOAL-HF1 study evaluating AC01 in patients with heart failure with reduced ejection fraction (HFrEF), …

AnaCardio’s AC01 Phase 1b/2a HFrEF Study Selected for Late-Breaking Science Presentation at the Heart Failure 2026 Congress

2026.03.262026.03.26 / STOCKHOLM, Sweden – March 26, 2026 – AnaCardio today announces that the results from GOAL-HF1, its Phase 1b/2a study of AC01 in patients with heart failure with reduced ejection fraction (HFrEF) have …

AnaCardio announces issuance of U.S. patent for AC01, strengthening protection into the 2040s

2026.03.112026.03.11 / Stockholm, Sweden and Lugano, Switzerland, March 11, 2026 – AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure and Helsinn …

AnaCardio Announces Completion of Target Enrollment in Phase 2a Study of AC01 in Heart Failure; Results Expected Year-end 2025

2025.09.172025.12.02 / Stockholm, Sweden, September 16, 2025 – AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents for heart failure, today announced that its ongoing Phase 2a study of …

AnaCardio strengthens leadership team with appointment of Philipp Mathieu as Chief Financial Officer

2025.09.022025.12.02 / Stockholm, Sweden, September 2, 2025 – AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing novel contractile agents to treat patients with heart failure, announces to …

AnaCardio announces positive scientific advice from the FDA and EMA, establishing a favourable development path for AC01 treatment of chronic HFrEF

2025.07.172025.09.22 / Alignment reached with both the FDA and EMA on key elements of the AC01 development strategy in chronic HFrEF, allowing for a lean, straightforward and coherent plan across both Europe and the USA …

Sound Contact:

Johan Kördel

Ph.D., Managing Partner